American Association for Cancer Research Immuno-Oncology (AACR IO) 2025 meeting, Los Angeles, CA
DATE: 2/24/2025
AACR IO 2025, February 24, 2025, Los Angeles, CA
Affinity Maturation and Characterization of a Novel O-Glycan Epitope Targeting Anti-Human Carcinoma Monoclonal Antibody (mAb) PB-223
DATE: 11/5/2024
SITC 2024 Poster Presentation
Reduction of circulating naive Tregs and gMDSCs and low levels of soluble MICA are prognostic for efficacy of combined NEO-201 and pembrolizumab
DATE: 6/1/2024
American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, May 31 – June 4, 2024, McCormick Place, Chicago, IL
The O-glycan epitope targeting anti-human carcinoma monoclonal antibody (mAb) NEO-201 can also target human regulatory T cells (Tregs)
DATE: 4/8/2024
American Association for Cancer Research (AACR) 2024 Annual Meeting, April 8, 2024, San Diego, CA, San Diego Convention Center.
Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as Independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
DATE: 11/1/2023
Poster title: Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as Independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
CICON 2023, CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference in Milan, Italy, Milan Convention Center (Allianz MiCo), Friday September 22nd, 2023, 12:45-2:00 PM
DATE: 9/18/2023
Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver a Poster Presentation at the CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference in Milan, Italy CICON — International Cancer Immunotherapy Conference
Poster title: The anti-core 1 O-glycans targeting monoclonal antibody NEO-201 recognizes and reduces the quantity of naïve regulatory T cells in PBMCs of cancer patients
Place/Date/Time: Milan Convention Center (Allianz MiCo), Italy, on Friday September 22nd, 2023 (12:45-2:00 PM,) poster section B, poster #137.
A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human granulocytic myeloid-derived suppressor cells (gMDSCs) and regulatory T (Tregs) cells
DATE: 4/14/2023
American Association for Cancer Research (AACR) 2023 Annual Meeting, April 14 – 19, Orlando, FL, Orange County Convention Center.
Poster number: 3
Session Category: Clinical Research Excluding Trials
Session Title: Therapeutic Antibodies, Including Engineered Antibodies
Session Date and Time: Tuesday April 18, 2023, 1:30pm – 5:00pm
Location: Section 44
Abstract Presentation Number: 5654
SITC 2022 - Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022
DATE: 11/9/2022
Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
DATE: 6/5/2022
Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
DATE: 11/13/21
Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
DATE: 11/12/21
Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020
DATE: 06/22/2020
Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, to enhance immune killing of tumor.
DATE: 02/06/2020
Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors
DATE: 01/25/2020
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs)
DATE: 11/6/2019
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway
DATE: 7/1/2018
2016 ASCO Annual Meeting – A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).
DATE: 6/16/2016